Our Services
Medical Information
Helpful Resources
Published on: 10/22/2026
Most guidance suggests holding daily-dosed GLP-1 medications (such as liraglutide) on the day of the procedure, while weekly-dosed options (such as semaglutide or tirzepatide) are typically paused about one week beforehand. Newer multi-society recommendations lean toward a more individualized approach, sometimes allowing the medication to continue alongside a 24-hour clear liquid diet before anesthesia. The timing can shift depending on the dose, how long you have been on the drug, whether you have diabetes, your GI symptoms, and the type of surgery planned. Never stop or adjust the medication without first speaking to your surgeon, anesthesiologist, and prescribing clinician, since blood sugar control and aspiration risk both matter here. There are several important factors to consider, so see below to understand more.
If you are weighing a surgery date, uncertain about medication timing, or noticing symptoms like nausea, vomiting, bloating, or feeling full long after eating, it helps to get clarity before you walk into the pre-op appointment. A free, instant, online symptom check can help you organize what you are experiencing, flag issues that may affect anesthesia safety, and point you toward the right next steps and the right questions to ask your care team. It takes just a few minutes, costs nothing, and gives you a clearer starting point than guessing on your own.
Last reviewed for medical accuracy: 10/22/2026
Planning for surgery involves careful coordination of your medications. If you’re taking a GLP-1 receptor agonist (GLP-1 RA) such as tirzepatide (Mounjaro), you’ll want to understand how it may affect your procedure and when to pause it. Below is a clear overview based on current expert and guideline recommendations.
GLP-1 RAs work by slowing gastric emptying and improving blood sugar control. While this is helpful for diabetes and weight management, slower stomach emptying can:
Because of these factors, many anesthesiologists and surgeons recommend holding GLP-1 RAs around the time of surgery.
Guidelines aren’t uniform, but common practice includes:
• Hold the morning dose on the day of surgery for short-acting agents (e.g., exenatide).
• For long-acting agents (e.g., semaglutide, dulaglutide), consider stopping at least 24–48 hours before.
• Resume once you’re tolerating clear liquids or your care team gives the go-ahead.
Since tirzepatide (Mounjaro) has a longer half-life—approximately 5 days—timing may differ slightly.
While high-quality trials on perioperative tirzepatide are still emerging, expert consensus suggests:
Minor Procedures (local anesthesia, low aspiration risk)
Major or Upper GI Procedures (general anesthesia, moderate to high aspiration risk)
Emergency Surgery
Stopping any diabetes medication can affect your glucose levels. To stay on track:
If you ever notice signs of dangerously high or low blood sugar, seek medical attention immediately.
Always speak to a doctor or your surgical/anesthesia team for personalized advice—especially if you have other health conditions or are facing a high-risk procedure. If you experience any life-threatening or serious symptoms, seek emergency care right away.
(References)
* Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17. PMID: 35579691; PMCID: PMC9112245.
* Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024 Sep 1;184(9):1056-1064. doi: 10.1001/jamainternmed.2024.2525. PMID: 38976257; PMCID: PMC11231910.
* Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7. PMID: 39761578.
* Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025 Aug;26(8):e13929. doi: 10.1111/obr.13929. Epub 2025 Apr 4. PMID: 40186344.
* Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V, ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. PMID: 40305708.
* Ciudin A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, Bertrand M, Curteis T, Clark LJ, Fan L, Sapin H, Bergmann JF. Indirect comparative efficacy and safety of tirzepatide 10 and 15≉mg versus semaglutide 2.4≉mg for the management of obesity and overweight in patients with type 2 diabetes. Diabetes Obes Metab. 2025 Sep;27(9):4709-4719. doi: 10.1111/dom.16508. Epub 2025 Jun 19. PMID: 40537987; PMCID: PMC12326929.
* Hocking SL, Scott DA, Remedios ML, Horowitz M, Story DA, Greenfield JR, Boussioutas A, Devereaux B, Andrikopoulos S, Shaw JE, Olesnicky BL. 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists. Anaesth Intensive Care. 2025 Sep;53(5):300-306. doi: 10.1177/0310057X251355288. Epub 2025 Aug 14. PMID: 40814081; PMCID: PMC12420935.
* Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surg. 2025 Nov 1;160(11):1232-1239. doi: 10.1001/jamasurg.2025.3590. PMID: 40960852; PMCID: PMC12444648.
* Tan YW, Shang M, Davis S, Gananadha S. GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis. Langenbecks Arch Surg. 2025 Oct 10;410(1):295. doi: 10.1007/s00423-025-03831-4. Epub 2025 Oct 10. PMID: 41071360; PMCID: PMC12513976.
* Sibal R, Balamurugan G, Langley J, Graham Y, Mahawar K. Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery? Nutrients. 2025 Nov 23;17(23). doi: 10.3390/nu17233659. Epub 2025 Nov 23. PMID: 41373949; PMCID: PMC12693348.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.